Human Vaccines Project, New York, NY 10119, USA.
Human Immunomics Initiative, Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA 02115, USA.
Sci Transl Med. 2021 Feb 3;13(579). doi: 10.1126/scitranslmed.abd1525.
Development of safe and effective COVID-19 vaccines is a global priority and the best hope for ending the COVID-19 pandemic. Remarkably, in less than 1 year, vaccines have been developed and shown to be efficacious and are already being deployed worldwide. Yet, many challenges remain. Immune senescence and comorbidities in aging populations and immune dysregulation in populations living in low-resource settings may impede vaccine effectiveness. Distribution of vaccines among these populations where vaccine access is historically low remains challenging. In this Review, we address these challenges and provide strategies for ensuring that vaccines are developed and deployed for those most vulnerable.
开发安全有效的 COVID-19 疫苗是全球的当务之急,也是终结 COVID-19 大流行的最佳希望。令人瞩目的是,在不到 1 年的时间里,疫苗已被研发出来并证实有效,且已在全球范围内投入使用。然而,仍有许多挑战存在。免疫衰老和老龄化人群中的合并症,以及资源匮乏环境中人群的免疫失调,可能会阻碍疫苗的有效性。在这些疫苗接种历史较低的人群中分配疫苗仍然具有挑战性。在这篇综述中,我们将探讨这些挑战,并提供策略以确保为最脆弱的人群开发和部署疫苗。